An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.

Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

TN's U.S. Rep. Diana Harshbarger (R-01) has introduced the 340B Access Act to ensure savings benefit everyone, including ...

The AHA and several safety-net providers argue that an upcoming mandatory rebate pilot violates administrative law, imposes millions in costs, and threatens patient care in vulnerable communities.

Ten medications accounted for nearly one-third of 340B program-covered outpatient drugs in 2024, according to a Dec. 11 report.  The Health Resources and Services Administration, an HHS agency, ...

Hospital groups raise issues with 340B rebate pilot program citing cash flow, administrative costs, and unclear rebate denials risks.

Congress must pass Rep. Diana Harshbarger's bipartisan proposal to ensure federal 340B dollars are used as intended.

NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing ...

Three expert witnesses at a recent Senate HELP Committee hearing outlined weaknesses and misaligned incentives driving growth in the 340B drug pricing program.

SPRINGFIELD – President Donald Trump’s signature domestic policy bill, passed this summer, will cost Baystate Health $146.7 ...